A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes Mellitus

Overview

The purpose of this study is to evaluate the safety and potential effectiveness of CCX140-B in subjects with Type 2 diabetes mellitus.

Full Title of Study: “A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes Mellitus”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Triple (Participant, Care Provider, Investigator)
  • Study Primary Completion Date: October 2010

Detailed Description

The primary objective of this study is to evaluate the safety and tolerability of CCX140-B in subjects with Type 2 diabetes mellitus (T2DM) based on subject incidence of adverse events. The secondary objectives of this study include evaluation of the effect of CCX140-B on several measures of effectiveness commonly used in the evaluation of diabetes medications.

Interventions

  • Drug: Placebo
    • Placebo capsules once daily
  • Drug: pioglitazone
    • pioglitazone 30 mg tablet once daily
  • Drug: CCX140-B
    • CCX140-B capsules once daily (Group C)
  • Drug: CCX140-B
    • CCX140-B capsules once daily (Group D)

Arms, Groups and Cohorts

  • Placebo Comparator: Placebo
  • Active Comparator: Active control
  • Experimental: Active Study Medication (Group C)
    • CCX140-B
  • Experimental: Active Study Medication (Group D)
    • CCX140-B

Clinical Trial Outcome Measures

Primary Measures

  • Subject incidence of adverse events
    • Time Frame: 28 days

Secondary Measures

  • Effect on fasting plasma glucose concentration
    • Time Frame: 28 days

Participating in This Clinical Trial

Key Inclusion Criteria:

  • Diagnosed type 2 diabetes mellitus – Must have a body mass index ≥25 and <45 kg/m2, but if body mass index is ≥25 and <28 kg/m2, then waist circumference must be >94 cm for men and >80 cm for women – Must be on a stable dose of metformin for at least 8 weeks prior to randomization – Hemoglobin A1c (HbA1c) of 6.5 to 10.0% inclusive and fasting plasma glucose 135 to 270 mg/dL inclusive at Screening Key Exclusion Criteria:

  • Type 1 diabetes mellitus or history of diabetic ketoacidosis – Received insulin treatment within 12 weeks of randomization – Received chronic (more than 7 days) systemic glucocorticoid treatment within 12 weeks of randomization – Received sulfonylurea, thiazolidinedione, exenatide, or any other glucose lowering treatment (other than metformin) within 8 weeks of randomization – Symptomatic congestive heart failure requiring prescription medication, clinically evident peripheral edema, poorly-controlled hypertension (systolic blood pressure >160 or diastolic blood pressure >100), history of unstable angina, myocardial infarction or stroke within 6 months of randomization, or chronic renal failure – History or presence of drug-induced myopathy, drug-induced creatine kinase elevation, or leukopenia (WBC count <3.5 x 10(9)/L) – History or presence of any form of cancer within the 5 years prior to randomization, with the exception of excised basal cell or squamous cell carcinoma of the skin, or cervical carcinoma in situ or breast carcinoma in situ that has been excised or resected completely and is without evidence of local recurrence or metastasis – Fasting serum triglyceride >400 mg/dL

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • ChemoCentryx
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Pirow MD, Study Director, Amgen

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.